Clinical Trials Logo

Filter by:
NCT ID: NCT06089395 Not yet recruiting - Clinical trials for Poor Ovarian Response

The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR)

Start date: June 1, 2024
Phase: Early Phase 1
Study type: Interventional

Relying on the Department of Gynecology of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine and chaoyang hospital of Capital medical university, this randomized controlled clinical study was carried out to investigate the application of kidney tonifying herbs to patients with poor ovarian response(POR). A total of 76 patients with POR were collected and stratified district groups were randomly divided into a test group and a control group, with 38 patients included in each group. The experimental group was intervented with JJGS granules + coenzyme Q10 simulant, and the control group was intervened with coenzyme Q10 + JJGS granules simulant. AMH, serum basal sex hormone, AFC, TCM syndrome score, modified Kupperman scale and pregnancy status were observed before and after treatment to investigate the effects of Jiajian Guishen granules on the ovarian function of POR patients.

NCT ID: NCT06089382 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Start date: November 1, 2023
Phase: Phase 3
Study type: Interventional

To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after hepatectomy.

NCT ID: NCT06089369 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) for patients with hepatocellular carcinoma and microvascular invasion (MVI) after hepatectomy.

NCT ID: NCT06088433 Not yet recruiting - Clinical trials for Coronary Heart Disease

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

Start date: November 15, 2023
Phase: Phase 4
Study type: Interventional

The present study is aimed to determine the safety and efficacy of Ticagrelor single antiplatelet therapy (SAPT) in patients with primary coronary small vessel disease at high risk of bleeding after drug coated balloon (DCB) therapy.

NCT ID: NCT06088056 Not yet recruiting - Breast Cancer Clinical Trials

A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

Start date: November 2023
Phase: Phase 2
Study type: Interventional

This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases.

NCT ID: NCT06087510 Not yet recruiting - Dexmedetomidine Clinical Trials

Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes

Start date: January 2024
Phase: Phase 4
Study type: Interventional

Chronic postsurgical pain (CPSP) refers to pain that occurs or increases after surgery and lasts longer than 3 months. Severe acute postoperative pain is one of the major risk factors of CPSP. Spinal correction surgery is associated with severe pain due to large trauma and long duration. Ketamine and esketamine are N-methyl-D-aspartate receptor antagonists; they have antihyperalgesic effects and may reduce CPSP. Dexmedetomidine is an alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effect; it is frequently used as an adjuvant to postoperative analgesia. In a previous trial of 200 patients after scoliosis correction surgery, mini-dose esketamine-dexmedetomidine in combination with opioids significantly improved analgesia and sleep quality but did not reduce CPSP. The authors speculate that increasing esketamine dose in the combination may further improve analgesia and, therefore, reduce the occurrence of CPSP.

NCT ID: NCT06087484 Not yet recruiting - Emotional Distress Clinical Trials

The Effect of Mindfulness Intervention for Emotional Distress of Insomnia People

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

Exploring the Effectiveness of a mindfulness intervention for Insomniacs with Emotional Distress Comparing the intervention effects of two mindfulness interventions

NCT ID: NCT06085378 Not yet recruiting - Type 2 Diabetes Clinical Trials

Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

TK-SEEK
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.

NCT ID: NCT06085261 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

COPD: A Multi-center Supervised Tele-rehabilitation Study

COPDMUST
Start date: November 2023
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease(COPD) patients could benefit from pulmonary rehabilitation(PR) in better managing of the disease and its symptoms and in avoiding future relapses and hospitalizations. However, due to a large number of drop outs from PR, lack of professionals, and the (Corona Virus Disease 2019) COVID-19 epidemic, the PR has been underutilized, leading to a need for investigation of updated forms. The study aims to investigate the effects of a home-based PR program using minimal accessories, facilitated with wearable activity trackers and smartphones.

NCT ID: NCT06084286 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Start date: October 30, 2023
Phase: Phase 1
Study type: Interventional

Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer. The CLDN18.2/PD-L1 dual-targeting CAR-T will be investigated in patients with CLDN18.2-positive advance solid tumors.